Drugs / KK4277
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05411016 | Aug 2022 → Dec 2024 overdue | cutaneous lupus erythematosus, systemic lupus erythematosus | Kyowa Kirin, Inc. | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-27 | SBI Biotech Co., Ltd. | SBIバイオテックが導出したSBI-9674（KK4277）におけるマイルストーン達成のお知らせ sbibiotech.jp ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KK4277 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05411016 ↗ |
| Route | Intravenous | “KK4277 is administered single dose or multiple dose by IV or SC injection” NCT05411016 ↗ |
| Route | Subcutaneous | “KK4277 is administered single dose or multiple dose by IV or SC injection” NCT05411016 ↗ |